avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2022-12-4-285-292avk-1481Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESНовые диагностические возможности определения активности язвенного колита: роль нейтрофиловNew Diagnostic Possibilities for Determining the Activity of Ulcerative Colitis: The Role of NeutrophilsБолотоваЕ. В.BolotovaE. V.

Краснодар

Krasnodar

ЮмукянК. А.YumukyanK. A.

Краснодар

Krasnodar

ДудниковаА. В.DudnikovaA. V.

Краснодар

Krasnodar

ФГБОУ ВО КубГМУ Минздрава РоссииРоссияState budgetary educational institution of higher professional education «Kuban state medical university» Ministry of health of the Russian FederationRussian FederationФГБОУ ВО КубГМУ Минздрава России; Государственное бюджетное учреждение здравоохранения «Научно-исследовательский институт — Краевая клиническая больница № 1 им. С.В. Очаповского»РоссияState budgetary educational institution of higher professional education «Kuban state medical university» Ministry of health of the Russian Federation; State Public Health Budget Institution Scientific Research Institute — Ochapovsky Regional Clinic Hospital of Krasnodar Region Public Health MinistryRussian Federation202231072022124285292Copyright © Болотова Е.В., Юмукян К.А., Дудникова А.В., 20222022Болотова Е.В., Юмукян К.А., Дудникова А.В.Bolotova E.V., Yumukyan K.A., Dudnikova A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/1481

Заболеваемость язвенным колитом в последние годы растет, и его развитие в молодом возрасте стало тенденцией, которая прогностически неблагоприятна. Клиническая картина язвенного колита часто расплывчата, что приводит к изначально ошибочному диагнозу. Оценка эффективности лечения и риска рецидива язвенного колита, требующая инвазивного вмешательства — одна из основных диагностических проблем. Целью исследования был анализ данных современной научной литературы о неинвазивных биомаркерах язвенного колита. Проанализированы данные зарубежных и отечественных статей по теме исследования, опубликованных в Pubmed и eLibrary за последние 5-10 лет. Биомаркеры нейтрофильного происхождения являются перспективным направлением в первичной диагностике и оценке активности язвенного колита.

The incidence of ulcerative colitis has been increasing in recent years, and its manifestation at a young age has become a trend that is prognostically unfavorable. The clinical picture of ulcerative colitis is often vague, which leads to an initially erroneous diagnosis. One of the main problems is to assess the effectiveness of treatment and the risk of recurrence of ulcerative colitis, which requires invasive intervention. The aim of the study was to analyze the data of modern scientific literature on noninvasive biomarkers of ulcerative colitis. The data of foreign and domestic articles on the research topic published in Pubmed and eLibrary over the past 5-10 years are analyzed. Biomarkers of neutrophil origin are a promising direction in the primary diagnosis and assessment of ulcerative colitis activity.

язвенный колитвоспалительные заболевания кишечниканейтрофилынеинвазивные биомаркерыulcerative colitisinflammatory bowel diseasesneutrophilsnoninvasive biomarkersReferencesNg SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018; 390(10114): 2769−2778. doi: 10.1016/S0140-6736(17)32448-0Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018; 390(10114): 2769−2778. doi: 10.1016/S0140-6736(17)32448-0Маев И.В., Шелыгин Ю.А., Скалинская М.И., и др. Патоморфоз воспалительных заболеваний кишечника. Вестник Российской академии медицинских наук. 2020; 75(1): 27-35. doi:10.15690/vramn1219Maev I.V., Shelygin Y.A., Skalinskaya M.I., et al. The pathomorphosis of inflammatory bowel diseases. Annals of the Russian academy of medical sciences. 2020; 75(1): 27-35 doi:10.15690/vramn1219 [In Russian]Тертычный А.С., Ахриева Х.М., Маев И.В., др. Проблемы диагностики гистологической ремиссии у больных с воспалительными заболеваниями кишечника. Архив патологии. 2017; 79(3): 3-9. doi:10.17116/patol20177933-9Tertychny A S, Akhrieva Kh M, Maev I V et al. Diagnostic problems of histological remission in patients with inflammatory bowel disease. Arkhiv Patologii. 2017; 79(3): 3-9 doi:10.17116/patol20177933-9 [In Russian]Tang L, Xu M. Candidate polymorphisms and susceptibility to inflammatory bowel disease: A systematic review and meta-analysis. Gene. 2020; 30; 753: 144814. doi: 10.1016/j.gene.2020.144814Tang L, Xu M. Candidate polymorphisms and susceptibility to inflammatory bowel disease: A systematic review and meta-analysis. Gene. 2020; 30; 753: 144814. doi: 10.1016/j.gene.2020.144814Wu PB, Qian R, Hong C, et al. Association between PTGER4 polymorphisms and inflammatory bowel disease risk in Caucasian: A meta-analysis. Medicine (Baltimore). 2020; 99(34): e19756. doi: 10.1097/MD.0000000000019756.Wu PB, Qian R, Hong C, et al. Association between PTGER4 polymorphisms and inflammatory bowel disease risk in Caucasian: A meta-analysis. Medicine (Baltimore). 2020; 99(34): e19756. doi: 10.1097/MD.0000000000019756.Zhao M, Feng R, Ben-Horin S, et al. Systematic review with metaanalysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022; 55(3): 266-276. doi: 10.1111/apt.16703Zhao M, Feng R, Ben-Horin S, et al. Systematic review with metaanalysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022; 55(3): 266-276. doi: 10.1111/apt.16703Zhong Y, Zhang Z, Lin Y, Wu L. The Relationship Between Helicobacter pylori and Inflammatory Bowel Disease. Arch Iran Med. 2021; 1; 24(4): 317-325. doi: 10.34172/aim.2021.44Zhong Y, Zhang Z, Lin Y, Wu L. The Relationship Between Helicobacter pylori and Inflammatory Bowel Disease. Arch Iran Med. 2021; 1; 24(4): 317-325. doi: 10.34172/aim.2021.44Lambert K, Pappas D, Miglioretto C et al. Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2021; 54(6): 742-754. doi: 10.1111/apt.16549Lambert K, Pappas D, Miglioretto C et al. Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2021; 54(6): 742-754. doi: 10.1111/apt.16549Халиф И.Л., Шапина М.В., Головенко А.О., и др. Течение хронических воспалительных заболеваний кишечника и методы их лечения, применяемые в Российской Федерации (результаты многоцентрового популяционного одномоментного наблюдательного исследования). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; 28(3): 54−62. doi:10.22416/1382-4376-2018-28-3-54-62Khalif IL, Shapina MV, Golovenko AO, et al. Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based onestage observational study). Russian Journal Gastroenterology, Hepatology, Coloproctology. 2018; 28(3): 54−62. doi:10.22416/1382-4376-2018- 28-3-54-62 [In Russian]Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol. 2021; 15(6): 665-674. doi: 10.1080/17474124.2021.1880892Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol. 2021; 15(6): 665-674. doi: 10.1080/17474124.2021.1880892Solitano V, D’Amico F, Allocca M., et al. Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? Therap Adv Gastroenterol. 2021; 14: 17562848211005692. doi: 10.1177/17562848211005692Solitano V, D’Amico F, Allocca M., et al. Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? Therap Adv Gastroenterol. 2021; 14: 17562848211005692. doi: 10.1177/17562848211005692Arkteg CB, Wergeland Sørbye S, Buhl Riis L, et al. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One. 2021; 16(3): e0248224. doi: 10.1371/journal.pone.0248224Arkteg CB, Wergeland Sørbye S, Buhl Riis L, et al. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One. 2021; 16(3): e0248224. doi: 10.1371/journal.pone.0248224Shah J, Dutta U, Das A, et al. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. JGH Open. 2019; 4(3): 382-386. doi: 10.1002/jgh3.12260Shah J, Dutta U, Das A, et al. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. JGH Open. 2019; 4(3): 382-386. doi: 10.1002/jgh3.12260Muthas D, Reznichenko A, Balendran CA, et al. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol. 2017; 52(2): 125-135. doi: 10.1080/00365521.2016.1235224.Muthas D, Reznichenko A, Balendran CA, et al. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol. 2017; 52(2): 125-135. doi: 10.1080/00365521.2016.1235224.Singh UP, Singh NP, Murphy EA, et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016; 77: 44-49. doi:10.1016/j.cyto.2015.10.008Singh UP, Singh NP, Murphy EA, et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016; 77: 44-49. doi:10.1016/j.cyto.2015.10.008Arkteg CB, Wergeland Sørbye S, Buhl Riis L, et al.Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One. 2021; 16(3): e0248224. doi:10.1371/journal.pone.0248224Arkteg CB, Wergeland Sørbye S, Buhl Riis L, et al.Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One. 2021; 16(3): e0248224. doi:10.1371/journal.pone.0248224Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem. 2018; 87: 161- 190. doi: 10.1016/bs.acc.2018.07.005Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem. 2018; 87: 161- 190. doi: 10.1016/bs.acc.2018.07.005Drury B, Hardisty G, Gray RD, Ho GT. Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation. Cell Mol Gastroenterol Hepatol. 2021; 12(1): 321-333. doi: 10.1016/j.jcmgh.2021.03.002Drury B, Hardisty G, Gray RD, Ho GT. Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation. Cell Mol Gastroenterol Hepatol. 2021; 12(1): 321-333. doi: 10.1016/j.jcmgh.2021.03.002Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017; 7(1): 2669. doi: 10.1038/s41598-017-02835-5Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017; 7(1): 2669. doi: 10.1038/s41598-017-02835-5Nemakayala DR, Cash BD. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go? Curr Opin Gastroenterol. 2019; 35(1): 58-62. doi: 10.1097/MOG.0000000000000493Nemakayala DR, Cash BD. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go? Curr Opin Gastroenterol. 2019; 35(1): 58-62. doi: 10.1097/MOG.0000000000000493Magro F, Lopes S, Coelho R et al. Portuguese IBD Study Group [GEDII]. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. J Crohns Colitis. 2017; 11(4): 435-444. doi: 10.1093/ecco-jcc/jjw170Magro F, Lopes S, Coelho R et al. Portuguese IBD Study Group [GEDII]. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. J Crohns Colitis. 2017; 11(4): 435-444. doi: 10.1093/ecco-jcc/jjw170Hart L, Chavannes M, Kherad O, et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. J Crohns Colitis. 2020; 14(1): 46-52. doi: 10.1093/ecco-jcc/jjz107Hart L, Chavannes M, Kherad O, et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. J Crohns Colitis. 2020; 14(1): 46-52. doi: 10.1093/ecco-jcc/jjz107MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015; 110(6): 802-19; quiz 820. doi: 10.1038/ajg.2015.120MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015; 110(6): 802-19; quiz 820. doi: 10.1038/ajg.2015.120Frin AC, Filippi J, Boschetti G, et al. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Dig Liver Dis. 2017; 49(1): 11-16. doi: 10.1016/j.dld.2016.09.001Frin AC, Filippi J, Boschetti G, et al. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Dig Liver Dis. 2017; 49(1): 11-16. doi: 10.1016/j.dld.2016.09.001Sakuraba A, Nemoto N, Hibi N, et al. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol. 2021; 21(1): 197. doi: 10.1186/s12876-021-01788-4Sakuraba A, Nemoto N, Hibi N, et al. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol. 2021; 21(1): 197. doi: 10.1186/s12876-021-01788-4Grabherr F, Effenberger M, Pedrini A, et al. Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19. Clin Transl Gastroenterol. 2021; 12(1): e00293. doi: 10.14309/ctg.0000000000000293Grabherr F, Effenberger M, Pedrini A, et al. Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19. Clin Transl Gastroenterol. 2021; 12(1): e00293. doi: 10.14309/ctg.0000000000000293Jangi S, Holmer AK, Dulai PS, et al. Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Trea tment Endpoint.J Crohns Colitis. 2021; 15(4): 567-574. doi: 10.1093/ecco-jcc/jjaa184Jangi S, Holmer AK, Dulai PS, et al. Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Trea tment Endpoint.J Crohns Colitis. 2021; 15(4): 567-574. doi: 10.1093/ecco-jcc/jjaa184Langhorst J, Boone J, Lauche R, et al. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial, Journal of Crohn’s and Colitis. 2016; 10(7): 786–794. doi: 10.1093/ecco-jcc/jjw044Langhorst J, Boone J, Lauche R, et al. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial, Journal of Crohn’s and Colitis. 2016; 10(7): 786–794. doi: 10.1093/ecco-jcc/jjw044Rubio MG, Amo-Mensah K, Gray JM, et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2019; 10(5): 54-63. doi: 10.4291/wjgp. v10.i5.54Rubio MG, Amo-Mensah K, Gray JM, et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2019; 10(5): 54-63. doi: 10.4291/wjgp. v10.i5.54Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010; 59(9): 1207-12. doi: 10.1136/gut.2010.211755Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010; 59(9): 1207-12. doi: 10.1136/gut.2010.211755Faubion WA Jr, Fletcher JG, O’Byrne S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn’s disease activity: role of crosssectional imaging. Am J Gastroenterol. 2018; 108(12): 1891-900. doi: 10.1038/ajg.2013.354Faubion WA Jr, Fletcher JG, O’Byrne S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn’s disease activity: role of crosssectional imaging. Am J Gastroenterol. 2018; 108(12): 1891-900. doi: 10.1038/ajg.2013.354Wang Y, Pei F, Wang X, et al. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Int J Clin Exp Pathol. 2015; 8(10): 12319-32Wang Y, Pei F, Wang X, et al. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Int J Clin Exp Pathol. 2015; 8(10): 12319-32Osterman MT, Aberra FN, Cross R, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology. 2014; 12(11): 1887,1893 e3.Osterman MT, Aberra FN, Cross R, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology. 2014; 12(11): 1887,1893 e3.Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFa-blocking agents in IBD. J Crohn’s Colitis. 2013; 7(9): 730-5. doi:10.1016/j. crohns.2012.10.018Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFa-blocking agents in IBD. J Crohn’s Colitis. 2013; 7(9): 730-5. doi:10.1016/j. crohns.2012.10.018Нестерова И.В, Колесникова Н.В., Чудилова Г.А., и др. Нейтрофильные гранулоциты: новый взгляд на «старых игроков» на иммунологическом поле. Иммунология. 2015; 4: 257-263Nesterova I.V., Kolesnikova N.V., CHudilova G.A., et al. Neutrophil granulocytes: a new look at the “old players” in the immunological field. Immunology. 2015; 4: 257-263 [In Russian]O’Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm. 2015; 2015: 964131. doi: 10.1155/2015/964131O’Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm. 2015; 2015: 964131. doi: 10.1155/2015/964131Sandborn WJ, Bhandari BR, Fogel R, et al. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016; 44(2): 157-69Sandborn WJ, Bhandari BR, Fogel R, et al. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016; 44(2): 157-69Thorsvik S, Damås JK, Granlund AV, et al. Fecal neutrophil gelatinaseassociated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol. 2017; 32(1): 128-135. doi: 10.1111/jgh.13598Thorsvik S, Damås JK, Granlund AV, et al. Fecal neutrophil gelatinaseassociated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol. 2017; 32(1): 128-135. doi: 10.1111/jgh.13598de Bruyn M, Arijs I, De Hertogh G, et al. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn’s Disease. J Crohns Colitis. 2015; 9(12): 1079-87. doi: 10.1093/eccojcc/jjv148de Bruyn M, Arijs I, De Hertogh G, et al. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn’s Disease. J Crohns Colitis. 2015; 9(12): 1079-87. doi: 10.1093/eccojcc/jjv148Wang J, Ortiz C, Fontenot L, et al. High circulating elafin levels are associated with Crohn’s disease-associated intestinal strictures. PLoS One. 2020; 15(4): e0231796. doi: 10.1371/journal.pone.0231796Wang J, Ortiz C, Fontenot L, et al. High circulating elafin levels are associated with Crohn’s disease-associated intestinal strictures. PLoS One. 2020; 15(4): e0231796. doi: 10.1371/journal.pone.0231796Zhang W, Teng G, Wu T, et al.Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(12): 2134-2141. doi: 10.1097/MIB.0000000000001252Zhang W, Teng G, Wu T, et al.Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(12): 2134-2141. doi: 10.1097/MIB.0000000000001252Barry R, Ruano-Gallego D, Radhakrishnan ST, et al. Faecal neutrophil elastase-antiprotease balance reflects colitis severity. Mucosal Immunol. 2020;13(2):322-333. doi: 10.1038/s41385-019-0235-4Barry R, Ruano-Gallego D, Radhakrishnan ST, et al. Faecal neutrophil elastase-antiprotease balance reflects colitis severity. Mucosal Immunol. 2020;13(2):322-333. doi: 10.1038/s41385-019-0235-4Jakimiuk K, Gesek J, Atanasov AG, et al. Flavonoids as inhibitors of human neutrophil elastase. J Enzyme Inhib Med Chem. 2021; 36(1): 1016-1028. doi: 10.1080/14756366.2021.1927006Jakimiuk K, Gesek J, Atanasov AG, et al. Flavonoids as inhibitors of human neutrophil elastase. J Enzyme Inhib Med Chem. 2021; 36(1): 1016-1028. doi: 10.1080/14756366.2021.1927006Curciarello R, Sobande T, Jones S, et al. Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. J Inflamm Res. 2020; 13: 233-243. doi: 10.2147/JIR.S234710Curciarello R, Sobande T, Jones S, et al. Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. J Inflamm Res. 2020; 13: 233-243. doi: 10.2147/JIR.S234710Mizuochi T, Arai K, Kudo T, et al. Diagnostic accuracy of serum proteinase 3 antineutrophil cytoplasmic antibodies in children with ulcerative colitis. J Gastroenterol Hepatol. 2021; 36(6): 1538-1544. doi: 10.1111/jgh.15296.Mizuochi T, Arai K, Kudo T, et al. Diagnostic accuracy of serum proteinase 3 antineutrophil cytoplasmic antibodies in children with ulcerative colitis. J Gastroenterol Hepatol. 2021; 36(6): 1538-1544. doi: 10.1111/jgh.15296.Xu Y, Xu F, Li W, et al. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Scand J Gastroenterol. 2020; 55(7): 806-813. doi: 10.1080/00365521. 2020.178192Xu Y, Xu F, Li W, et al. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Scand J Gastroenterol. 2020; 55(7): 806-813. doi: 10.1080/00365521. 2020.178192De Bruyn M, Ceuleers H, Hanning N, et al. Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis. Int J Mol Sci. 2021; 22(19): 10711. doi: 10.3390/ijms221910711De Bruyn M, Ceuleers H, Hanning N, et al. Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis. Int J Mol Sci. 2021; 22(19): 10711. doi: 10.3390/ijms221910711Malech HL, DeLeo FR, Quinn MT. The Role of Neutrophils in the Immune System: An Overview. Methods Mol Biol. 2020; 2087: 3-10. doi: 10.1007/978-1-0716-0154-9_1Malech HL, DeLeo FR, Quinn MT. The Role of Neutrophils in the Immune System: An Overview. Methods Mol Biol. 2020; 2087: 3-10. doi: 10.1007/978-1-0716-0154-9_1Fujita M, Kawabata H, Oka T, et al. Rare Case of Adult Autoimmune Neutropenia Successfully Treated with Prednisolone. Intern Med. 2017; 56(11): 1415-1419. doi: 10.2169/internalmedicine.56.7619Fujita M, Kawabata H, Oka T, et al. Rare Case of Adult Autoimmune Neutropenia Successfully Treated with Prednisolone. Intern Med. 2017; 56(11): 1415-1419. doi: 10.2169/internalmedicine.56.7619Planell N, Masamunt MC, Leal RF, et al. Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. J Crohns Colitis. 2017; 11(11): 1335-1346. doi: 10.1093/ecco-jcc/jjx09Planell N, Masamunt MC, Leal RF, et al. Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. J Crohns Colitis. 2017; 11(11): 1335-1346. doi: 10.1093/ecco-jcc/jjx09

The authors declare that there are no conflicts of interest present.